

1 **Changes of the Commensal Microbiome during Treatment are Associated with Clinical**  
2 **Response in Nasopharyngeal Carcinoma Patients**

3

4 Tingting Huang<sup>a,b,c</sup>, Justine Debelius<sup>a</sup>, Alexander Ploner<sup>a</sup>, Xiling Xiao<sup>d</sup>, Tingting Zhang<sup>b,c</sup>,  
5 Kai Hu<sup>b,c</sup>, Zhe Zhang<sup>d</sup>, Rensheng Wang<sup>b,c,#</sup>, Weimin Ye<sup>a,#</sup>

6

7 <sup>a</sup>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm,  
8 Sweden

9 <sup>b</sup>Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical  
10 University, Nanning, P. R. China

11 <sup>c</sup> Radiation Oncology Clinical Medical Research Center of Guangxi, Nanning, Nanning, P. R.  
12 China

13 <sup>d</sup>Department of Otolaryngology-Head & Neck Surgery, First Affiliated Hospital of Guangxi  
14 Medical University, Nanning, P. R. China.

15

16 Running title: Microbiome is Associated with Clinical Response in NPC

17

18 # Address correspondence to Weimin Ye ([weimin.ye@ki.se](mailto:weimin.ye@ki.se)) and Rensheng Wang  
19 ([wangrenshenggxmu@gmail.com](mailto:wangrenshenggxmu@gmail.com)).

20 Weimin Ye and Rensheng Wang contributed equally to this work. Author order was  
21 determined by consortium policy.

## 22 **Abstracts**

23 The human microbiome has been suggested to be involved in the regulation of response to  
24 anticancer therapies. However, little is known regarding changes of commensal microbes in  
25 cancer patients during radiotherapy and whether these changes are associated with response to  
26 treatment. We conducted a prospective, longitudinal cohort with sixty-two newly diagnosed  
27 nasopharyngeal carcinoma (NPC) patients who were scheduled for radiotherapy-based  
28 treatment. Nasopharyngeal swabs were collected longitudinally before radiotherapy, during  
29 radiotherapy, and after radiotherapy. The nasopharyngeal microbiome was assessed using 16S  
30 rRNA amplicon sequencing. All patients were followed up to 24 months to define an early or  
31 late clinical response. We demonstrated the beta-diversity of the nasopharyngeal microbiome  
32 showed temporal changes throughout treatment. The magnitude of changes was stably and  
33 significantly different between the early and late responders. The temporal microbial  
34 networks among NPC patients with early response differed significantly from those with late  
35 response. Seven amplicon sequence variants (ASVs) mapped to *Corynebacterium* were lost  
36 during treatment. Twenty-eight abundant ASVs differed by patients' responses throughout  
37 treatment. Among them, 10 ASVs differed between the early responders and late responders  
38 before getting any treatment and the difference was consistent along the radiotherapy course.  
39 This study addressed the temporal changes of the nasopharyngeal microbiome in NPC  
40 patients during radiotherapy and suggested a significant association with clinical response.  
41 The subject-specific changes of the nasopharyngeal microbiome might serve as a potential  
42 predictor for clinical response to radiotherapy.

43

## 44 **Importance**

45 The human microbiome has been suggested to be involved in the regulation of response to  
46 anticancer therapies. However, little is known regarding changes of commensal microbes in  
47 cancer patients during radiotherapy and whether these changes have an impact on response to  
48 treatment. In this longitudinal study of nasopharyngeal carcinoma patients, we demonstrate  
49 that the temporal changes of the nasopharyngeal microbiome in NPC patients during  
50 radiotherapy-based treatment and suggest a significant association with patients' clinical  
51 response. We identify 28 abundant amplicon sequence variants differed significantly between  
52 the early and late responders throughout treatment. Among them, 10 are consistently differed  
53 by patients' responses. These subject-specific changes might serve as a potential predictor for  
54 clinical response to radiotherapy. To the best of our knowledge, this is the first example that  
55 the commensal microbiome may influence the response to radiotherapy-based treatment in  
56 cancer patients.

## 57 **Introduction**

58 The human commensal microbiome has been suggested to be involved in both carcinogenesis  
59 and in the regulation of response to anticancer therapies (1-4). Accumulating evidence  
60 suggests that the microbiome can substantially affect the effectiveness of chemotherapy and  
61 immunotherapy such as gemcitabine and immune checkpoint inhibitors (5, 6). Accordingly,  
62 there is a growing interest in identifying and targeting these microbes in the anti-cancer  
63 treatment. However, little is known regarding whether or how the microbiome may regulate  
64 the response to radiotherapy, which is critical to the realization of its potential (2, 3, 7). In part,  
65 this is due to a lack of well designed longitudinal studies looking at the relationship between  
66 microbes and response to radiotherapy is seldom studied (2, 3).

67

68 To address this knowledge gap, we conducted a prospective study to characterize the  
69 longitudinal patterns of the commensal microbiome among cancer patients during  
70 radiotherapy-based anti-cancer treatment and investigated whether the temporal changes of  
71 the microbiome might be associated with patients' clinical response. Nasopharyngeal  
72 carcinoma (NPC) is a malignant disease and endemic mainly in southern China and Southeast  
73 Asia (8). Radiotherapy is the essential mainstay of curative-intent treatment for the non-  
74 disseminated disease. Intensity-modulated radiation therapy (IMRT) contributes to the high 5-  
75 year survival rate of 68-80%, together with chemotherapy (9, 10). However, both local and  
76 distant failure after a first-line therapy remain key challenges which call for identification of  
77 novel indicators and modulators of clinical response. Hence, we prospectively collected  
78 nasopharyngeal swab samples during radiotherapy from a hospital-based NPC-patient cohort  
79 in southern China where NPC incidence rates exceed 10-15 per 100 000 person-years, about  
80 twenty times the rate in the western world (8). We hypothesized that the temporal change of

81 nasopharyngeal microbiome during radiotherapy might be associated with NPC patients'  
82 clinical responses.

83

## 84 **Results**

85 A total of 445 nasopharyngeal microbial profiles, corresponding to 39 NPC patients, were  
86 analyzed. Thirty-six (92.3%) patients had advanced disease (stage III to IV<sub>B</sub>) at diagnosis. All  
87 of the NPC patients were treated with radiotherapy, 35 (89.7%) received concurrent  
88 chemotherapy including 25 (64.1%) who received induction chemotherapy or adjuvant  
89 chemotherapy. Twenty-seven patients (69.2%) with CR at the first clinical check-up were  
90 defined as early responders; the remaining 12 NPC patients achieved CR within 24 months of  
91 follow-up were defined as late responders (Supplementary Table S1).

92

### 93 **NPC patients' clinical responses are associated with the temporal changes of between-** 94 **sample diversity of nasopharyngeal microbiome during radiotherapy**

95 The overall pattern of beta-diversity of the nasopharyngeal microbiome was visualized in  
96 PCoA projections for both unweighted and weighted UniFrac distance (Supplementary Figure  
97 S1). In both PCoA projections, samples of early responders were relatively dissimilar with the  
98 samples of late responders along PC2 (explained 5.88% of the variation in the unweighted  
99 projection; and 12.93% of the variation in the weighted projection), while similar along PC1  
100 (13.23% in the unweighted, and 29.50% in the weighted) and PC3 (3.59% in the unweighted,  
101 and 7.84% in the weighted). By performing volatility analysis, the global variation (as an  
102 average) along PCs as a measure of longitudinal temporal volatility is presented in Figure 1.  
103 We saw a consistent shift along with the PC1 space with sampling time in both unweighted

104 and weighted panels, regardless of clinical response. In PC2 panels, distinct separations  
105 between early and late responders were observed throughout treatment, whereas the temporal  
106 trajectories were relatively stable in each group. Moreover, in PC3 space, a moderate  
107 separation between the trajectories of response groups was found in the unweighted panel  
108 while the trajectories in the weighted panel showed fluctuated and gradual directional changes  
109 throughout treatment regardless of response status. The changed volatilities found in the last  
110 few sampling time-points have a larger standard deviation compared to the previous time-  
111 points, which might be partially explained by low sample numbers. Patient compliance with  
112 sample collection varied.

113

114 We measured the rate of change in beta-diversity differences over radiotherapy in terms of the  
115 weighted UniFrac step length  $\Delta$ -wUF and tested whether  $\Delta$ -wUF changed over treatment and  
116 in response to the response status of NPC patients. We found statistically significant evidence  
117 for subject-specific differences (random effects) in baseline step length (intercept) as well as a  
118 change in step length over sampling time (slope,  $P$ -value = 0.0005) from linear mixed effect  
119 models (Supplementary Table S2). However, the across-subject average step length (fixed  
120 effect) appeared stable in Figure 2A, with no evidence for increasing or decreasing dynamic  
121 change ( $P$ -value = 0.4609). Adding the clinical response status improved the mixed effect  
122 model significantly ( $P$ -value = 0.0152). The best-fitting model including clinical response  
123 status retained stable for average step lengths for both early and late responders, with larger  
124 average step lengths for early responders compared to late responders (Figure 2B). Individual  
125 trajectories varied considerably between subjects, shown in Figure 2C.

126

127 **NPC patients' clinical responses are associated with the temporal trajectories of the**  
128 **abundant microbial features**

129 Seventy-three ASVs were identified as the abundant subset for feature-based analyses. A  
130 Procrustean randomization test and Mantel test based on the Bray-Curtis distance indicated a  
131 well concordance between the abundant subset and the full dataset (PROTEST: correlation =  
132 0.9669,  $P$ -value = 0.001, 999 permutations; Mantel test: correlation = 0.9506,  $P$ -value = 0.001,  
133 999 permutations; Supplementary Figure S2). NMIT evaluates interdependence networks,  
134 which summarized the temporal trajectories of the abundant subset over treatment of each  
135 NPC patient into a single distance. The NMIT distances differed between clinical response  
136 groups. We observed that the interdependence networks among patients with early response  
137 statistically significantly differed from those with a late response, and no statistically  
138 significance differences found within response groups (PERMANOVA:  $P$ -value = 0.014;  
139 permdisp:  $P$ -value = 0.315; 999 permutations). In Figure 3, the networks of the late  
140 responders varied widely, forming a spread ellipsoid-like cluster, compared to the early  
141 responders who formed a smaller and more constrained ellipsoid-like cluster. These clusters  
142 are dissimilar along PC1 and PC3, but relatively similar along PC2.

143

144 We investigated longitudinal changes in the abundant ASVs across all samples using a  
145 modified ANCOM-test. We identified seven abundant ASVs where more than 80% of ASV  
146 ratios were temporally correlated (Supplementary Figure S3, panel A), all members of genus  
147 *Corynebacterium*. There was a decrease in the relative abundance of all seven ASVs showed  
148 during treatment while most other ASVs remained stable over treatment course  
149 (Supplementary Table S3; and Figure S3, panel B to E).

150

151 To quantify ASV-based longitudinal differences between early and late responders, we  
152 applied SS-ANOVA. We identified 28 out of 73 abundant ASVs as differing significantly  
153 between early and late responders over treatment course, listed in Table 1 ( $P$ -value < 0.05,  
154 1500 permutations). Notable that, among these significant ASVs, 10 differed between the  
155 early responders and late responders before getting any treatment, and remained consistently  
156 different during radiotherapy. Additionally, there were 9 ASVs that were similar between  
157 response groups during the first one-third of treatment and became different until the  
158 completion. In contrast, 5 ASVs differed between groups at the beginning and was converged  
159 during treatment.

160

161 For better visualization of the temporal trajectories of the difference between the early and  
162 late responders, the log<sub>2</sub>-fold changes of the 73 abundant ASVs estimated by SS-ANOVA  
163 were plotted as a heatmap and clustered into three groups (Cluster A to C) (Figure 4, and  
164 Supplementary Table S4). We found 22 ASVs (30.1%) in Cluster A, which were more  
165 prevalent among the early responders while 12 of them were significantly different between  
166 response groups with an increased relative abundance along with treatment course. Among  
167 the significant ASVs, 4 were members of genus *Burkholderia* (gBurkh.39c8, gBurkh.6364,  
168 gBurkh.f802, and gBurkh.ee2f), 2 were genus *Acinetobacter* (gAcine.efe8, and gAcine.32b4),  
169 and the rest were members of genus *Corynebacterium* (gCoryn.ca4d), *Streptococcus*  
170 (gStrep.3ed3), *Brevundimonas* (gBrevu.1285), *Enhydrobacter* (gEnhyd.0ef3), *Candidatus*  
171 *Rhodoluna* (gCandi.9a10), and unspecified order Bacillales (oBacil.0094). In Cluster B  
172 (n=37), most of the ASVs had relatively small difference between response groups and were  
173 found no statistically significant difference across treatment. Four ASVs showing significant  
174 difference across treatment (assigned to genus *Corynebacterium* (gCoryn.1650, gCoryn.5ba9),  
175 unclassified family Methylobacteriaceae (fMethy.ebba), and unclassified family



176 Bradyrhizobiaceae (fBrady.cbae)). For Cluster C, 14 ASVs were more among the late  
177 responders compared to the early responders with dynamic trajectories (increased, decreased,  
178 and relatively stable in difference) over treatment. Twelve of them found statistically  
179 significant which were the members of genus *Acinetobacter* (gAcine.4f58, gAcine.4c95, and  
180 gAcine.dfae), genus *Thermus* (gTherm.b26c, gTherm.94db, and gTherm.087b), genus  
181 *Ralstonia* (gRalst.edc7 and gRalst.a529), genus *Corynebacterium* (gCoryn.ff32, gCoryn.0838),  
182 genus *Staphylococcus* (gStaph.ab0b), and unspecified family Caulobacteraceae (fCaulo.a200).

183

## 184 **Discussion**

185 In the present study, we have addressed temporal changes of the commensal microbiome in  
186 response to radiotherapy-based anticancer treatment among NPC patients for the first time. To  
187 be specific, the temporal changes in between-sample diversity of the nasopharyngeal  
188 microbiome and the abundant microbial features are associated with NPC patients' clinical  
189 responses. The longitudinal study design provided a comprehensive view of microbial  
190 diversity, an effective way for assessing the microbial correlation networks and an  
191 opportunity to reveal the degree of change of the abundant features between time points  
192 during the observation period (11). Notably, the subject-specific changes showed in our study  
193 might suggest a possibility of using the nasopharyngeal microbiome as a predictor for clinical  
194 response.

195

196 We observed that the UniFrac distances used for measuring beta-diversity qualitatively  
197 (unweighted) and quantitatively (weighted), on average, showed temporal changes throughout  
198 treatment (volatilities along PC1 explaining the largest amount of within-subject changes).  
199 Previous studies also described the progressive alteration in the oral microbiome during

200 radiotherapy among NPC patients (12), and the change in gut microbiome in patients after  
201 pelvic radiotherapy (13). Remarkably, we found distinct and consistent separations in  
202 volatility regarding patients' clinical responses along the PC2, which suggests that a global  
203 difference between the early and late responders might have existed before treatment and stay  
204 relatively stable afterward until the completion of radiotherapy. We further demonstrated that  
205 the magnitude of longitudinal global changes of the nasopharyngeal microbiome was  
206 significantly different between response groups, namely the average step length of the early  
207 responders was statistically, significantly larger than that of the late responders. However, the  
208 magnitude of changes appeared constant within each group along with treatment. These  
209 findings challenge the Anna Karenina principle, which suggests the positive prognosis is  
210 associated with community stability (14). It may implicate bacterial resilience to radiotherapy  
211 as a feature of delayed response. It is reasonable to imagine that such a community might be  
212 protective in some way against both radiation-induced perturbations on the microbiome as  
213 well as the host.

214

215 In the feature-based analysis, we observed similar characteristics in the NMIT analysis: the  
216 temporal changes in microbial networks of NPC patients over treatment were statistically  
217 significantly different regarding their clinical responses. The difference observed between  
218 groups was not due to a large degree of dispersion within groups. By looking at individual  
219 abundant ASV, genera known to dominate the human upper aerodigestive tract:  
220 *Corynebacterium*, *Staphylococcus*, *Acinetobacter*, and *Streptococcus* (15, 16), were also  
221 found dominant in our study. We found a significant and consistent loss of *Corynebacterium*  
222 (including 7 distinct ASVs) over treatment. Oral *Corynebacterium* was reported previously to  
223 decrease the risk of head and neck cancer, although the study did not include NPC (17).  
224 Members of the genera are also normally, temporally stable in Chinese adults (18).

225 Additionally, we observed that 28 out of 73 abundance ASVs were significantly different in  
226 abundance between the early and late responders during treatment. Notably, 10 ASVs  
227 primarily found in Cluster C differed between groups before the initiation of radiotherapy-  
228 based treatment and consistently differed until the completion. These results correspond to the  
229 characteristics observed in the diversity-based analyses above. Moreover, genera *Ralstonia*  
230 and *Thermus* have been previously identified as reagent contaminants (19). We found  
231 consistent signals for 4 ASVs from these genera (Ther-b26c, Ther-087b, Rals-edc7, and Rals-  
232 a529) between response groups, despite sample randomization across plates. These organisms  
233 were at very low abundance or absent in early responders, but present in late responders. Thus,  
234 the finding is unlikely solely due to contamination. Members of these extremophile genera are  
235 known to be radiation- or ROS-resistant, which suggests a potentially plausible biological  
236 mechanism for their inclusion in these communities (20). These findings suggest a possibility  
237 that these ASVs might be putative indicators of patients' response to radiotherapy-based  
238 treatment. . However, it is also important to note that some ASVs assigned to the same genus  
239 behaved differently, such as members of the genus *Acinetobacter* (gAcine.32b4 and  
240 gAcine.efe8 in Cluster A, compared to gAcine.4f58, gAcine.4c95, and gAcine.dfae in Cluster  
241 C), which may reflect niche specialization within the same genus (11).

242

243 While the results suggest a clear relationship between changes in the microbiome and  
244 treatment response, several open questions remain. First, previous studies in the literature  
245 focused mainly on potential associations between the commensal microbiome and the  
246 radiotherapy-induced side effects and comorbidities among cancer patients (12, 21-24), and  
247 rarely investigated the impact of microbiome on radiotherapy efficacy except a pilot study  
248 with a small sample size (n=3) which reported a relationship between the response to  
249 radiotherapy and the gut microbiome in pediatric cancer patients (25). It is, however, difficult

250 to compare our findings directly with most of the published data. Replication studies will be  
251 needed to determine if the microbiome can be used as a reliable indicator of treatment  
252 response in NPC. In addition, we acknowledge that the majority of our study subjects were  
253 NPC patients with stage III to IVb diseases (more than 90%) who were administrated  
254 concurrent chemo-radiotherapy (platinum-based) as recommended by clinical guidelines, and  
255 the analyses were not adjusted by therapeutic strategies due to a concern of low statistical  
256 power. The response to platinum-based chemotherapy has been reported to be modulated by  
257 gut microbiota, which influences the inflammation, immunity, and metabolism systematically  
258 (2, 26). Our analyses could not distinguish the contributions from radiotherapy and  
259 chemotherapy, separately. However, we considered that the nasopharyngeal microbiome  
260 might be affected mainly and heavily by radiotherapy with high energy X-ray in the  
261 nasopharynx. Last but not the least, some researchers suggest that microbiome affects the  
262 response to radiotherapy by modulating the damage-associated molecular pattern signals,  
263 however, the essential knowledge is yet deficient and the underlying mechanism is yet to be  
264 explored (2, 4, 27). Therefore, additional work is warranted to replicate our findings among  
265 similar study populations; and to address potential mechanisms, such as immune regulation  
266 and potential interaction between the nasopharyngeal microbiome and systemic  
267 immunotherapy.

268

269 In conclusion, this study demonstrated the temporal changes of the nasopharyngeal  
270 microbiome in NPC patients during radiotherapy-based treatment and suggested a significant  
271 association with clinical response. By focusing on NPC, a type of cancer where radiotherapy  
272 is the most common treatment, we hypothesize that the relationship between the microbiome  
273 and clinical response may hold true for other diseases and anatomical locations. These results  
274 shed new light on a possibility that the commensal microbiome may influence the response to

275 radiotherapy-based anticancer treatment in cancer patients, and call for larger longitudinal  
276 studies with long-term follow-up to understand the underlying mechanisms.

277

## 278 **Materials and Methods**

### 279 *Study design and setting*

280 This prospective study recruited newly diagnosed NPC patients in the First Affiliated Hospital  
281 of Guangxi Medical University, Guangxi Province located in southern China, between 2014  
282 and 2015. The study was approved by the Ethical Review Committee of the First Affiliated  
283 Hospital of Guangxi Medical University, China, and the Regional Ethical Review Board in  
284 Stockholm, Sweden. Written informed consent was obtained from all patients. A total of 76  
285 NPC patients were recruited and 62 were enrolled in this study. Details are given in  
286 Supplementary Data (Supplementary Method S1 and Figure S4).

287

288 All patients were treated according to the standards of clinical practice (details are given in  
289 Supplementary Method S2). All patients received the first clinical check-up at 3 months after  
290 the completion of radiotherapy and were followed up for 24 months. Patients who achieved a  
291 complete response (CR) in the first check-up were classified as early responders and patients  
292 who achieved CR between the first and the end of follow-up were designated late responders.

293

### 294 *Sample collection and processing*

295 In total 870 nasopharyngeal swabs were collected from 62 NPC patients. A protocol  
296 including enzymatic lysis and bead beating for DNA extraction was used. The indexed library

297 targeting the V3-V4 hypervariable regions of the 16S rRNA gene was prepared using samples  
298 with sufficiently high-quality DNA. Extraction controls, PCR amplification controls, and  
299 bacterial reference controls were included in each step. After quality and quantity checking, a  
300 total of 526 16S rRNA-based libraries and 85 control libraries were sequenced by Beijing  
301 Genomics Institute (BGI, Wuhan, China), using a 300-bp paired-end strategy on Illumina  
302 Miseq according to the manufacturer's instructions. Details are given in Supplementary Data  
303 (Supplementary Method S3 and S4, and Figure S4).

304

#### 305 *Data denoising and pre-processing*

306 Raw sequences were quality filtered and denoised using *deblur* to generated amplicon  
307 sequence variants (ASVs) in QIIME 2 (v. 2019-10) (28-31). A phylogenetic tree was built  
308 using fragment insertion into the August 2013 Greengenes 99% tree and taxonomic  
309 assignments using a naïve Bayesian classifier trained against the same reference (32-34). The  
310 dataset was filtered to remove samples without valid clinical information (4 individuals with  
311 56 samples), ASVs assigned to mitochondrial rRNA (35), and samples with fewer than 1,500  
312 reads (25 samples). Finally, 445 samples derived from 39 NPC patients were retained, with  
313 around 3 million high quality reads assigned to 9,320 ASVs (33 phyla, 107 classes, 192 orders,  
314 336 families, and 724 genera). Between-sample diversity (beta-diversity) was estimated after  
315 samples were rarefied to 1,500 reads per sample (36). Feature-based analyses were performed  
316 using a representative subset of ASVs with at least 0.1% relative abundance in at least 10% of  
317 samples, as abundant ASVs (n=73). Two samples were removed due to the absence of  
318 abundant ASVs, retaining 443 samples. The concordance between the main ASVs dataset and  
319 the abundant ASVs subset was tested. Details are given in Supplementary Data  
320 (Supplementary Method S5 and Figure S5).

321

322 *Statistical analysis*

323 In this study, the analyses of global patterns were mainly focused on beta-diversity using  
324 unweighted and weighted UniFrac distance (37, 38). Principal Coordinate Analysis (PCoA)  
325 projections were used to visualize between-sample difference (39). The longitudinal pattern of  
326 nasopharyngeal microbiome along each principle coordinate (PC) was visualized using  
327 volatility analysis in QIIME 2 2019.10 (*q2-longitudinal*) (40). The weighted UniFrac distance  
328 matrix was further used to measure the rate of change which differed over treatment. The  
329 change in an individual community between two sequential treatment occasions was  
330 quantified as the weighted UniFrac distance between successive samples ( $\Delta\text{-wUF} = \text{wUF}_{(t)} -$   
331  $\text{wUF}_{(t-1)}$ ), corresponding to the weighted Unifrac step length of an individual's trajectory  
332 through nasopharyngeal microbial space.  $\Delta\text{-wUF}$  was modeled as a function of treatment  
333 occasion (sampling time) via linear mixed effect models (LMEs, considering treatment,  
334 temporal and inter-individual effects) with the *lme4* package (v. 1.1-19) in R 3.5.1 (41).  
335 Differences between nested models were tested via likelihood ratio tests, while Akaike's  
336 information criterion (AIC) was used to compare general models.

337

338 In the analyses of feature-based patterns, Non-parametric Microbial Interdependence Test  
339 (NMIT) was used to determine longitudinal sample similarity as a function of temporal  
340 microbial composition network over treatment (42). We further eliminated three patients who  
341 had less than five successive samples, retaining 434 samples of 36 patients, to make the  
342 analysis robust and efficient. In brief, the Spearman correlations between any pair of 73  
343 abundant ASVs were computed based on their relative abundance; distances between any two  
344 of patients' correlation matrices were calculated based on a Frobenius norm; PCoA was used

345 to visualize the similarity among patients. The difference of microbial networks between  
346 response groups was tested by the permutation-based extension of multivariate analysis of  
347 variance (PERMANOVA) test (43) and the multivariate dispersion test (permdisp) (44).  
348 NMIT, PERMANOVA, and permdisp were carried out by QIIME 2 2019.10, and PCoA was  
349 plotted in R 3.5.1. On the other hand, the longitudinal patterns of the 73 abundant ASVs  
350 individually were also analyzed. The temporal relationship for the abundant ASVs was  
351 evaluated using a modified analysis of composition of microbiomes (ANCOM)-based  
352 approach using Spearman correlation (45). A normalized ANCOM W statistic was calculated  
353 as the fraction of tests where the raw p-values were less than 0.05, and a normalized W of  
354 more than 80% was considered statistically significant. This test was applied to both the raw  
355 data, and the ratios between time points. Additionally, the longitudinal differences in  
356 abundance (log<sub>2</sub>-transformed) of abundant ASVs between early and late responders were  
357 modeled via Smoothing-spline ANOVA (SS-ANOVA) (46) using *metagenomeSeq* package (v.  
358 1.24.0); the predicted changing trajectories of abundant ASVs were grouped into hierarchical  
359 clustering using Ward's method (Ward's D2) and displayed as a heatmap using *Heatplus*  
360 package (v. 2.32.1) (47) in R.3.6.2.

361

### 362 *Data availability*

363 Raw sequencing data and metadata are deposited in ENA under accession XXXXX.



364 **Acknowledgements**

365 We acknowledge funding from the Swedish Cancer Society (2016/510 to W. Ye) and the  
366 Swedish Research Council (2015-02625, 2015-06268, 2017-05814 to W. Ye); the National  
367 Natural Science Foundation of China (81360405 to R. Wang) and the Guangxi (China)  
368 Science and Technology Program Project (GK AD17129013 to R. Wang); the Natural  
369 Science Foundation of Guangxi Medical University for Junior Scientists (GXMUYSF201203  
370 to T. Huang). T. Huang was also partly supported by a grant from the China Scholarship  
371 Council (201408450018).

372 We would like to thank the patients recruited in this study, and the clinical staff in the  
373 Department of Radiation Oncology in the First Affiliated Hospital of Guangxi Medical  
374 University (Nanning, P. R. China). We are grateful to Dr. Zhe Zhang, Dr. Xiaoying Zhou, Dr.  
375 Xue Xiao, and their research group for lab support.

376 T. Huang had full access to all of the data in the study and takes responsibility for the  
377 integrity of the data and the accuracy of the data analysis. T. Huang, Z. Zhang, R. Wang, and  
378 W. Ye conceived and designed the study. T. Huang, R. Wang, and W. Ye received funding. T.  
379 Huang, T. Zhang, and K. Hu recruited patients, collected samples and follow-up information.  
380 T. Huang and X. Xiao performed laboratory assays. Z. Zhang, R. Wang, and W. Ye  
381 contributed resources. T. Huang, J. Debelius, and A. Ploner analyzed the data, prepared  
382 figures. T. Huang, J. Debelius, A. Ploner, R. Wang, and W. Ye interpreted the results. T.  
383 Huang, J. Debelius, and A. Ploner wrote the manuscript. All authors edited the manuscript  
384 and approval of the final draft.

385 On behalf of all authors, the corresponding authors declared that they have no potential  
386 financial and non-financial competing interests.

## 387 **References**

- 388 1. Garrett WS. 2015. Cancer and the microbiota. *Science* 348:80-6.
- 389 2. Roy S, Trinchieri G. 2017. Microbiota: a key orchestrator of cancer therapy. *Nat Rev Cancer*  
390 17:271-285.
- 391 3. McQuade JL, Daniel CR, Helmink BA, Wargo JA. 2019. Modulating the microbiome to improve  
392 therapeutic response in cancer. *Lancet Oncol* 20:e77-e91.
- 393 4. Raza MH, Siraj S, Arshad A, Waheed U, Aldakheel F, Alduraywish S, Arshad M. 2017. ROS-  
394 modulated therapeutic approaches in cancer treatment. *J Cancer Res Clin Oncol*  
395 doi:10.1007/s00432-017-2464-9.
- 396 5. Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, Gavert N, Zwang Y,  
397 Cooper ZA, Shee K, Thaiss CA, Reuben A, Livny J, Avraham R, Frederick DT, Ligorio M,  
398 Chatman K, Johnston SE, Mosher CM, Brandis A, Fuks G, Gurbatri C, Gopalakrishnan V, Kim M,  
399 Hurd MW, Katz M, Fleming J, Maitra A, Smith DA, Skalak M, Bu J, Michaud M, Trauger SA,  
400 Barshack I, Golan T, Sandbank J, Flaherty KT, Mandinova A, Garrett WS, Thayer SP, Ferrone  
401 CR, Huttenhower C, Bhatia SN, Gevers D, Wargo JA, Golub TR, Straussman R. 2017. Potential  
402 role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug  
403 gemcitabine. *Science* 357:1156-1160.
- 404 6. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, Fluckiger A, Messaoudene  
405 M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren  
406 K, Mondragon L, Jacquelot N, Qu B, Ferrere G, Clemenson C, Mezquita L, Masip JR, Naltet C,  
407 Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel  
408 B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G,  
409 Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G,  
410 Zitvogel L. 2018. Gut microbiome influences efficacy of PD-1-based immunotherapy against  
411 epithelial tumors. *Science* 359:91-97.


- 412 7. Helmink BA, Khan MAW, Hermann A, Gopalakrishnan V, Wargo JA. 2019. The microbiome,  
413 cancer, and cancer therapy. *Nat Med* 25:377-388.
- 414 8. Chua MLK, Wee JTS, Hui EP, Chan ATC. 2016. Nasopharyngeal carcinoma. *Lancet* 387:1012-  
415 1024.
- 416 9. Lee AW, Ma BB, Ng WT, Chan AT. 2015. Management of Nasopharyngeal Carcinoma: Current  
417 Practice and Future Perspective. *J Clin Oncol* 33:3356-64.
- 418 10. Hong RL, Hsiao CF, Ting LL, Ko JY, Wang CW, Chang JTC, Lou PJ, Wang HM, Tsai MH, Lai SC, Liu  
419 TW. 2018. Final results of a randomized phase III trial of induction chemotherapy followed by  
420 concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with  
421 stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG)  
422 1303 Study. *Ann Oncol* 29:1972-1979.
- 423 11. Goodrich JK, Di Rienzi SC, Poole AC, Koren O, Walters WA, Caporaso JG, Knight R, Ley RE.  
424 2014. Conducting a microbiome study. *Cell* 158:250-262.
- 425 12. Zhu XX, Yang XJ, Chao YL, Zheng HM, Sheng HF, Liu HY, He Y, Zhou HW. 2017. The Potential  
426 Effect of Oral Microbiota in the Prediction of Mucositis During Radiotherapy for  
427 Nasopharyngeal Carcinoma. *Ebiomedicine* 18:23-31.
- 428 13. Wang A, Ling Z, Yang Z, Kiela PR, Wang T, Wang C, Cao L, Geng F, Shen M, Ran X, Su Y, Cheng  
429 T, Wang J. 2015. Gut microbial dysbiosis may predict diarrhea and fatigue in patients  
430 undergoing pelvic cancer radiotherapy: a pilot study. *PLoS One* 10:e0126312.
- 431 14. Zaneveld JR, McMinds R, Vega Thurber R. 2017. Stress and stability: applying the Anna  
432 Karenina principle to animal microbiomes. *Nat Microbiol* 2:17121.
- 433 15. Wang H, Dai W, Feng X, Zhou Q, Wang H, Yang Y, Li S, Zheng Y. 2018. Microbiota Composition  
434 in Upper Respiratory Tracts of Healthy Children in Shenzhen, China, Differed with Respiratory  
435 Sites and Ages. *Biomed Res Int* 2018:6515670.

- 436 16. Hang J, Zavaljevski N, Yang Y, Desai V, Ruck RC, Macareo LR, Jarman RG, Reifman J, Kuschner  
437 RA, Keiser PB. 2017. Composition and variation of respiratory microbiota in healthy military  
438 personnel. *PLoS One* 12:e0188461.
- 439 17. Hayes RB, Ahn J, Fan X, Peters BA, Ma Y, Yang L, Agalliu I, Burk RD, Ganly I, Purdue MP,  
440 Freedman ND, Gapstur SM, Pei Z. 2018. Association of Oral Microbiome With Risk for  
441 Incident Head and Neck Squamous Cell Cancer. *JAMA Oncol* 4:358-365.
- 442 18. Utter DR, Mark Welch JL, Borisy GG. 2016. Individuality, Stability, and Variability of the  
443 Plaque Microbiome. *Front Microbiol* 7:564.
- 444 19. Salter SJ, Cox MJ, Turek EM, Calus ST, Cookson WO, Moffatt MF, Turner P, Parkhill J, Loman  
445 NJ, Walker AW. 2014. Reagent and laboratory contamination can critically impact sequence-  
446 based microbiome analyses. *BMC Biol* 12:87.
- 447 20. Battista JR, Earl AM, Park MJ. 1999. Why is *Deinococcus radiodurans* so resistant to ionizing  
448 radiation? *Trends Microbiol* 7:362-5.
- 449 21. Reis Ferreira M, Andreyev HJN, Mohammed K, Truelove L, Gowan SM, Li J, Gulliford SL,  
450 Marchesi JR, Dearnaley DP. 2019. Microbiota- and Radiotherapy-Induced Gastrointestinal  
451 Side-Effects (MARS) Study: A Large Pilot Study of the Microbiome in Acute and Late-Radiation  
452 Enteropathy. *Clin Cancer Res* 25:6487-6500.
- 453 22. Hou J, Zheng H, Li P, Liu H, Zhou H, Yang X. 2018. Distinct shifts in the oral microbiota are  
454 associated with the progression and aggravation of mucositis during radiotherapy. *Radiother  
455 Oncol* doi:10.1016/j.radonc.2018.04.023.
- 456 23. Zhang J, Liu H, Liang X, Zhang M, Wang R, Peng G, Li J. 2015. Investigation of salivary function  
457 and oral microbiota of radiation caries-free people with nasopharyngeal carcinoma. *PLoS  
458 One* 10:e0123137.
- 459 24. Wang Z, Wang Q, Wang X, Zhu L, Chen J, Zhang B, Chen Y, Yuan Z. 2019. Gut microbial  
460 dysbiosis is associated with development and progression of radiation enteritis during pelvic  
461 radiotherapy. *J Cell Mol Med* 23:3747-3756.

- 462 25. Sahly N, Moustafa A, Zaghoul M, Salem TZ. 2019. Effect of radiotherapy on the gut  
463 microbiome in pediatric cancer patients: a pilot study. *PeerJ* 7:e7683.
- 464 26. Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, Salcedo R,  
465 Back T, Cramer S, Dai RM, Kiu H, Cardone M, Naik S, Patri AK, Wang E, Marincola FM, Frank  
466 KM, Belkaid Y, Trinchieri G, Goldszmid RS. 2013. Commensal bacteria control cancer response  
467 to therapy by modulating the tumor microenvironment. *Science* 342:967-70.
- 468 27. Al-Qadami G, Van Sebille Y, Le H, Bowen J. 2019. Gut microbiota: implications for  
469 radiotherapy response and radiotherapy-induced mucositis. *Expert Rev Gastroenterol*  
470 *Hepatol* 13:485-496.
- 471 28. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, Alexander H, Alm EJ,  
472 Arumugam M, Asnicar F, Bai Y, Bisanz JE, Bittinger K, Brejnrod A, Brislawn CJ, Brown CT,  
473 Callahan BJ, Caraballo-Rodriguez AM, Chase J, Cope EK, Da Silva R, Diener C, Dorrestein PC,  
474 Douglas GM, Durall DM, Duvallet C, Edwardson CF, Ernst M, Estaki M, Fouquier J, Gauglitz JM,  
475 Gibbons SM, Gibson DL, Gonzalez A, Gorlick K, Guo J, Hillmann B, Holmes S, Holste H,  
476 Huttenhower C, Huttley GA, Janssen S, Jarmusch AK, Jiang L, Kaehler BD, Kang KB, Keefe CR,  
477 Keim P, Kelley ST, Knights D, et al. 2019. Reproducible, interactive, scalable and extensible  
478 microbiome data science using QIIME 2. *Nat Biotechnol* 37:852-857.
- 479 29. Bokulich NA, Kaehler BD, Rideout JR, Dillon M, Bolyen E, Knight R, Huttley GA, Gregory  
480 Caporaso J. 2018. Optimizing taxonomic classification of marker-gene amplicon sequences  
481 with QIIME 2's q2-feature-classifier plugin. *Microbiome* 6:90.
- 482 30. Amir A, McDonald D, Navas-Molina JA, Kopylova E, Morton JT, Zech Xu Z, Kightley EP,  
483 Thompson LR, Hyde ER, Gonzalez A, Knight R. 2017. Deblur Rapidly Resolves Single-  
484 Nucleotide Community Sequence Patterns. *mSystems* 2.
- 485 31. Bokulich NA, Subramanian S, Faith JJ, Gevers D, Gordon JJ, Knight R, Mills DA, Caporaso JG.  
486 2013. Quality-filtering vastly improves diversity estimates from Illumina amplicon sequencing.  
487 *Nat Methods* 10:57-9.

- 488 32. McDonald D, Price MN, Goodrich J, Nawrocki EP, DeSantis TZ, Probst A, Andersen GL, Knight  
489 R, Hugenholtz P. 2012. An improved Greengenes taxonomy with explicit ranks for ecological  
490 and evolutionary analyses of bacteria and archaea. *ISME J* 6:610-8.
- 491 33. Wang Q, Garrity GM, Tiedje JM, Cole JR. 2007. Naive Bayesian classifier for rapid assignment  
492 of rRNA sequences into the new bacterial taxonomy. *Appl Environ Microbiol* 73:5261-7.
- 493 34. Janssen S, McDonald D, Gonzalez A, Navas-Molina JA, Jiang L, Xu ZZ, Winker K, Kado DM,  
494 Orwoll E, Manary M, Mirarab S, Knight R. 2018. Phylogenetic Placement of Exact Amplicon  
495 Sequences Improves Associations with Clinical Information. *mSystems* 3.
- 496 35. Emelyanov VV. 2001. Evolutionary relationship of Rickettsiae and mitochondria. *FEBS Lett*  
497 501:11-8.
- 498 36. Weiss S, Xu ZZ, Peddada S, Amir A, Bittinger K, Gonzalez A, Lozupone C, Zaneveld JR,  
499 Vazquez-Baeza Y, Birmingham A, Hyde ER, Knight R. 2017. Normalization and microbial  
500 differential abundance strategies depend upon data characteristics. *Microbiome* 5:27.
- 501 37. Lozupone CA, Hamady M, Kelley ST, Knight R. 2007. Quantitative and qualitative beta  
502 diversity measures lead to different insights into factors that structure microbial  
503 communities. *Appl Environ Microbiol* 73:1576-85.
- 504 38. Lozupone C, Knight R. 2005. UniFrac: a new phylogenetic method for comparing microbial  
505 communities. *Appl Environ Microbiol* 71:8228-35.
- 506 39. Vazquez-Baeza Y, Pirrung M, Gonzalez A, Knight R. 2013. EMPeror: a tool for visualizing high-  
507 throughput microbial community data. *Gigascience* 2:16.
- 508 40. Bokulich NA, Dillon MR, Zhang Y, Rideout JR, Bolyen E, Li H, Albert PS, Caporaso JG. 2018. q2-  
509 longitudinal: Longitudinal and Paired-Sample Analyses of Microbiome Data. *mSystems* 3.
- 510 41. Bates D, Mächler M, Bolker B, Walker S. 2015. Fitting Linear Mixed-Effects Models Using  
511 lme4. 2015 67:48.

- 512 42. Zhang Y, Han SW, Cox LM, Li H. 2017. A multivariate distance-based analytic framework for  
513 microbial interdependence association test in longitudinal study. *Genet Epidemiol* 41:769-  
514 778.
- 515 43. Anonymous. *Permutational Multivariate Analysis of Variance (PERMANOVA)*, p 1-15, Wiley  
516 StatsRef: Statistics Reference Online doi:10.1002/9781118445112.stat07841.
- 517 44. Anderson MJ, Ellingsen KE, McArdle BH. 2006. Multivariate dispersion as a measure of beta  
518 diversity. *Ecol Lett* 9:683-93.
- 519 45. Mandal S, Van Treuren W, White RA, Eggesbo M, Knight R, Peddada SD. 2015. Analysis of  
520 composition of microbiomes: a novel method for studying microbial composition. *Microb*  
521 *Ecol Health Dis* 26:27663.
- 522 46. Joseph N. Paulson HT, Hector Corrada Bravo. 2017. Longitudinal differential abundance  
523 analysis of microbial marker-gene surveys using smoothing splines. *bioRxiv*  
524 doi:<https://doi.org/10.1101/099457>.
- 525 47. Ploner A. 2018. Heatplus: Heatmaps with row and/or column covariates and colored clusters.  
526 <https://github.com/alexploner/Heatplus>,
- 527




528

529 **Figure 1. Normalized volatility of the nasopharyngeal microbiome in 39 patients during**  
530 **a 7-week treatment course.**

531 The longitudinal pattern of the nasopharyngeal microbiome of 39 patients over 7-week  
532 treatment was explored by Principle Coordinate Analysis (PCoA) projection along principle  
533 coordinate1 (PC1), PC2 and PC3 with regard to sampling time. The volatility analysis was  
534 used to visualize the mean distances based on UniFrac distance matrices in each PC space.  
535 The left of each panel reflects mean volatility of all individual trajectories referred to the  
536 unweighted UniFrac distance matrix, and the right side referred to the weighted UniFrac  
537 distance matrix. The consecutive numbers on the bottom indicate the sampling time points (0  
538 = before radiotherapy). The trace represents the mean and the shaded is the standard deviation  
539 of each sampling time point. The curves in each PC space are marked by response status (a  
540 brown curve showing the early responders, a green curve showing the late responders).






541

542 **Figure 2. Group-wise and individual  $\Delta$ -wUFs during treatment reflect the rate of change**  
543 **in the community.**

544 The weighted UniFrac step length  $\Delta$ -wUF of an individual's trajectory through  
545 nasopharyngeal microbial space was modeled as a function of treatment occasion (sampling  
546 time) via linear mixed effect models (LMEs), including within-individual random effects. The  
547 consecutive numbers on the bottom of each panel indicate the sampling time points. We  
548 explored (Panel A) the average step length across all individuals and (Panel B) average step  
549 length by clinical response. The moving average is shown as a thin line with shaded pointwise  
550 95% confidence intervals; the thicker line is the estimated average step length (fixed effect)  
551 from the mixed model which takes into account the individual-level variations in step length  
552 over sampling time. We also explored the predicted individual step length trajectories for


553 early and late responders (Panel C). The horizontal axis indicates the sampling time during  
554 treatment and the vertical axis the mean step length  $\Delta$ -wUFs.



555

556 **Figure 3. Differences in the interdependence networks of nasopharyngeal microbiome**  
557 **between the early and late responders.**

558 Non-parametric microbial interdependence test (NMIT) was used to determine longitudinal  
559 sample similarity as a function of temporal microbial composition networks over treatment.  
560 The similarities of nasopharyngeal microbial networks among NPC patients were visualized  
561 by Principle Coordinate Analysis (PCoA) projection. The first 3 axes in PCoA explain 15.03%  
562 of the variation in total (PCo1=5.67%, PCo2=4.91%, PCo3=4.45%). Each dot in the PCoA  
563 space is an indicator representing the temporal microbial network of one NPC patient. Brown  
564 dots are the early responders, green the late responders. The cloud representing the minimum-  
565 volume ellipsoid covers 80% of the data of each group. Panels A-D reflect different  
566 orientations of the same 3-dimension plot (screenshots from a 3-dimension PCoA projection).



567

568 **Figure 4. The predicted log<sub>2</sub>-fold change trajectories of 73 abundant ASVs between the**  
569 **early and late responders.**

570 The predicted log<sub>2</sub>-fold change trajectories of 73 amplicon sequence variants (ASVs) between  
571 the early responders and late responders generated from SS-ANOVA were grouped into  
572 hierarchical clusters using Ward's D2 and displayed as a heatmap. Each row in the heatmap  
573 represents the trajectory across treatment of each ASV. The consecutive numbers on the  
574 bottom of heatmap indicate the sampling time points (1 = before radiotherapy, 20 = end of  
575 radiotherapy). ASVs with higher abundance in early responders are brown; those with more  
576 abundance in late responders are teal. Three clusters are marked as A to C. The vertical bars  
577 on the right side indicate whether the trend in difference across treatment is statistically  
578 significant ( $P$ -value < 0.05 for the black bars, otherwise not).

579 **Table 1. Twenty-eight abundant ASVs were detected with significant differences**  
 580 **between early and late responders during a 7-week treatment course.**

ASV-ID	Taxonomy <sup>a</sup>	Time intervals <sup>b</sup>		Permutative <sup>c</sup>
		Start	End	P-value
gBurkh.6364	g__Burkholderia	7	20	0.005
gBurkh.39c8	g__Burkholderia	8	20	0.007
gCandi.9a10	g__Candidatus Rhodoluna	14	20	0.009
oBacil.0094	o__Bacillales	8	20	0.011
gAcine.32b4	g__Acinetobacter	7	20	0.011
gAcine.efe8	g__Acinetobacter	18	20	0.011
gEnhyd.0ef3	g__Enhydrobacter	10	20	0.018
gStrep.3ed3	g__Streptococcus	1	17	0.020
gBrevu.1285	g__Brevundimonas	1	19	0.024
gCoryn.ca4d	g__Corynebacterium	8	20	0.029
gBurkh.f802	g__Burkholderia	14	20	0.044
gBurkh.ee2f	g__Burkholderia	7	20	0.049
fMethy.cbae	f__Methylobacteriaceae	5	11	0.017
gCoryn.1650	g__Corynebacterium	1	12	0.026
fBrady.ebba	f__Bradyrhizobiaceae	6	20	0.029
gCoryn.5ba9	g__Corynebacterium	1	13	0.043
gTherm.b26c	g__Thermus	1	20	0.003
fCaulo.a200	f__Caulobacteraceae	2	20	0.003
gTherm.94db	g__Thermus	1	19	0.003
gTherm.087b	g__Thermus	1	20	0.004
gAcine.4f58	g__Acinetobacter	1	20	0.005
gRalst.edc7	g__Ralstonia	1	20	0.006
gAcine.4c95	g__Acinetobacter	1	20	0.009
gAcine.dfae	g__Acinetobacter	1	20	0.013
gCoryn.ff32	g__Corynebacterium	1	12	0.016
gStaph.ab0b	g__Staphylococcus	1	14	0.021
gCoryn.0838	g__Corynebacterium	1	15	0.025
gRalst.a529	g__Ralstonia	4	20	0.041

581 <sup>a</sup>: Taxonomy assignment. “g\_\_” refers to genus; “f\_\_” refers to family; “o\_\_” refers to order.

582 <sup>b</sup>: Time intervals with significant difference; number refers to sampling time (1 = before radiotherapy,

583 20 = end of radiotherapy).

584 <sup>c</sup>: 1500 permutations.